Amgen Inc. (NASDAQ:AMGN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Amgen Inc. (NASDAQ:AMGN) has received a consensus rating of “Moderate Buy” from the twenty-six ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $351.6522.

Several equities analysts recently issued reports on the company. Argus raised their price target on Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a report on Friday. BMO Capital Markets raised their target price on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. The Goldman Sachs Group increased their price objective on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Amgen in a report on Wednesday, February 4th.

Insider Buying and Selling at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 10,908 shares of company stock valued at $3,674,966. 0.69% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Dogwood Wealth Management LLC grew its holdings in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the period. Anfield Capital Management LLC grew its stake in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Board of the Pension Protection Fund acquired a new position in Amgen in the fourth quarter valued at about $26,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the second quarter worth about $27,000. Finally, Manning & Napier Advisors LLC raised its position in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Down 2.2%

Shares of AMGN opened at $375.82 on Tuesday. The stock has a fifty day moving average price of $335.21 and a two-hundred day moving average price of $311.98. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen has a 52-week low of $261.43 and a 52-week high of $385.12. The company has a market cap of $202.37 billion, a price-to-earnings ratio of 26.41, a PEG ratio of 3.96 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the prior year, the firm earned $5.31 EPS. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts predict that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is presently 66.90%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.